Log in or Sign up for Free to view tailored content for your specialty!
Acute Kidney Injury News
FDA approves Lupkynis, first-ever oral therapy for lupus nephritis
The FDA has approved voclosporin as the first oral treatment for lupus nephritis in adult patients who are receiving background immunosuppressive therapy, according to a press release from Aurinia Pharmaceuticals.
Stress-related disorders linked to kidney disease progression, AKI
Swedish patients who had a stress-related disorder were more likely to experience chronic kidney disease progression and AKI compared with a population-matched control group.
Log in or Sign up for Free to view tailored content for your specialty!
‘Smaller, simpler, smarter’: Quanta officials review FDA-cleared portable dialysis system
Already commercially available in the United Kingdom, the SC+ portable hemodialysis system from Quanta Dialysis Technologies has received 510(k) clearance “setting the stage for [a] U.S. market launch,” according to a press release.
Transplanted kidneys from deceased donors with terminal AKI found safe, effective
Kidney transplantation with organs from donors who died after developing AKI conferred similar outcomes as transplant with non-AKI organs, according to study results.
SGLT2 inhibitors ‘best choice’ for reducing AKI risk vs other glucose-lowering drugs
For patients with type 2 diabetes, SGLT2 inhibitors conferred a lower risk of developing AKI than use of GLP-1 receptor agonists or dipeptidyl peptidase-4 inhibitors, according to a network meta-analysis of clinical trials.
FDA approves Benlysta, first treatment for lupus nephritis
The FDA has approved belimumab in intravenous and subcutaneous formulations for the treatment of lupus nephritis in adult patients who are receiving standard therapy, according to a press release from GlaxoSmithKline.
Study finds 30% of patients with AKI do not receive adequate follow-up
Research presented at the virtual ASN Kidney Week suggested 30% of patients hospitalized with AKI received inadequate follow-up, with medical risk factors being the “primary determinants” of care after hospitalization.
Acute kidney injury with COVID-19 shows potential for ‘lifetime’ impact
A study of U.S. veterans hospitalized with COVID-19 showed 32% developed AKI, with many not fully recovering kidney function by discharge. Black individuals were at greatest risk for AKI and resulting mortality.
Belimumab plus standard therapy boosts renal outcomes, reduces steroids in lupus nephritis
Adding belimumab to standard therapy improves renal outcomes, biomarker levels and overall disease activity among patients with lupus nephritis, according to a speaker at ACR Convergence 2020.
Machine-learning tool may help predict acute kidney injury in patients with COVID-19
Researchers from Icahn School of Medicine at Mount Sinai found a machine-learning model performed well in predicting risk for AKI and need for dialysis in patients hospitalized with COVID-19.
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read